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Jak-2 mutation frequency in patients with thrombocytosis 
 
 
 
Abstract 
Background: We aimed to investigate the etiologic causes and the existence of Janus 
kinase 2  mutation (JAK2) in cases with thrombocytosis. 
Methods: In this retrospective study, patients who were admitted to hematology clinic with 
thrombocytosis between 2013 and 2015 were investigated in terms of the etiological 
causes of thrombocytosis and the existence of JAK2 mutation. 
Results: We retrospectively evaluated 136 cases that underwent JAK2 mutation analysis 
due to ET preliminary diagnosis in our hematology clinic. The mean age of the patients 
was 56.7±15.3 years (range: 22-86 years) and 71 (52%) were males. JAK2 mutation was 
found to be positive in 58 (42%) of cases. The mean platelet counts of the cases were 
860.25×10
9
 / L (range: 455-1,105 10
9
 /L) and the mean spleen vertical length was 
135.1±21.6 mm (range: 110-220 mm). 
Conclusions: JAK2 mutation analysis and bone marrow biopsy are the two main 
procedures to diagnose primary thrombocytosis in adults with persistent thrombocytosis 
after excluding the causes of secondary thrombocytosis. Myeloproliferative neoplasms and 
essential thrombocytosis are the common causes of primary thrombocytosis in adults with 
persistent thrombocytosis, as myelodysplastic syndrome rarely causes primary 
thrombocytosis. 
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Thrombocytosis is seen as a primary disease (primary myeloproliferative diseases) 
or a reactive (secondary) to diseases of the bone marrow (1). Infections, severe iron 
deficiency, neoplasm, hemorrhage, hemolysis, inflammatory conditions, splenectomy, and 
some medications cause reactive thrombocytosis (1).
 
Chronic myeloproliferative disorders 
(CMDs) progress with proliferation in one or more hematopoietic cell populations 
accompanied with differentiation and maturation. Those include chronic myeloid leukemia 
(CML), polycythemia vera (PV), essential thrombocytosis (ET) and primary myelofibrosis 
(PMF) (2).
 
The CML is distinguished from others by the presence of Philadelphia (Ph) 
chromosome t (9:22) or BCR-ABL molecule, as PV, ET and PMF are called as Ph 
chromosome negative myeloproliferative disorders (3). Janus kinase 2 (JAK2) mutation 
was discovered in 2005 in Ph chromosome negative myeloproliferative disorders and was 
found in the whole of PV cases and about 50% of the ET and PMF cases (4, 5). According 
to the classification of the World Health Organization (WHO) in 2008, JAK2 positivity 
was accepted to be one of the major criteria in the diagnosis of Ph-negative 
myeloproliferative disorders (6).
 
JAK2 gene is also used as a diagnostic marker. It has 
been reported that the JAK2 mutation frequency in ET is about 50% and about 60% in all 
myeloproliferative disorders (MDs) (7).  
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There are not enough studies about the frequency of 
JAK2 mutation in ET and thrombocytosis cases yet (2). In 
this study, we aimed to investigate the etiologic causes of 
thrombocytosis and the existence of JAK2 mutation in cases 
with thrombocytosis, retrospectively. 
 
 
Methods 
In this retrospective study, the patients, who were 
admitted with thrombocytosis (platelet count > 450×10
9
 /L) 
that remained for at least three months, and followed up at 
the Hematology clinic of Ministry of Health Istanbul 
Training and Research Hospital between 2013 and 2015, 
were investigated in terms of the etiologic causes of 
thrombocytosis and existence of JAK2 mutation patients. 
The patients were evaluated based on patient files and 
hospital records.  
All causes of primary and secondary thrombocytosis 
were investigated. Patients initially underwent baseline tests 
such as a complete blood count, sedimentation, peripheral 
blood smear, CRP, ferritin, autoimmune disease tests (ANA, 
anti-DNA, RF etc.), Brucella tube agglutination test, ELISA 
(anti-HIV, anti-HCV, anti-HBs), urinalysis, stool blood test, 
cancer markers (CA 19-9, CEA, PSA), abdominal 
ultrasonography, chest x-ray, endoscopy, JAK2 mutation and 
Ph chromosome for the differential diagnosis of primary and 
secondary thrombocytosis.  
The etiologic causes of reactive thrombocytosis and 
clonal neoplasms other than ET have not been evaluated in 
our study. Infection-related thrombocytosis was generally 
referred as "inflammatory" and detailed. Diseases such as 
rheumatoid arthritis and systemic lupus were also referred as 
autoimmune diseases without reference to subgroups. 
SPSS Version15.0 for Windows program was used for 
the statistical analysis. Descriptive statistics were described 
as the number and percentage for the categorical variables; 
mean, standardized, minimum, maximum for the numerical 
variables.  
Mann-Whitney U test was used for independent 
numerical comparisons between the two groups that did not 
satisfy the normal distribution condition. The Kruskal Wallis 
test was performed because the independent group-to-group 
comparisons were not provided for the normal distribution 
condition of numerical variables. Subgroup analyses were 
performed by Mann-Whitney U test and interpreted by 
Bonferroni correction. The ratios of categorical variables 
between the groups were tested by chi-square analysis. 
Statistical significance levels of alpha were accepted as 
p<0.05. 
 
 
Results 
We retrospectively evaluated 136 cases that underwent 
JAK2 mutation analysis due to thrombocytosis as a 
preliminary diagnosis in the hematology clinic. The mean 
age of the patients was 56.7±15.3 years (range: 22-86 years) 
and 71 (52%) were males.  
The means age of males was 56.4±15.6 years and of 
females was 56.9±15.2 years, respectively. There was no 
statistically significant difference between males and females 
in terms of mean age (P=0.970).  
Bone biopsy was performed in 106 (77.9%) cases for the 
definite diagnosis. JAK2 mutation was found to be positive 
in 58 (42%) of cases. JAK2 mutation was found to be more 
frequent in males. The mean platelet counts of all cases were 
860.25×10
9
 / L (range: 455-1,105 10
9
 /L), and the mean 
spleen vertical length was 135.1±21.6 mm (range: 110-220 
mm).  
Primary thrombocytosis consisted of 75% of the cases in 
the etiology. The distribution of the diagnosis groups was ET 
in 59 (43%) cases, policytemia vera in 19 (14%) cases, 
inflammation in 18 (13%) cases, primary myelofibrosis in 9 
(6%) cases, myeloproliferative neoplasms (MPNs) in 9 (6%) 
cases, iron deficiency anemia (IDA) in 8 (5%) cases, 
splenectomy in 5 (3%) cases, CML in 3 (2%) cases, 
myelodysplastic syndrome (MDS) +MPN in 2 (1%) cases, 
malignancy in 2 (1%) cases, MDS in 1(1%) cases, and 
autoimmune disease in 1 (1%) case.  
The mean age of the cases with JAK2 mutation (p: 
0.004), the mean of spleen vertical lengths (p=0.004) and 
percentage of bone biopsy (p: 0.001) were found to be 
significantly higher than those without the JAK2 mutation. 
ET, PV, and PMF were recorded more frequently in patients 
with JAK2 mutation, whereas reactive causes (inflammation, 
DEA, splenectomy) were recorded predominantly in cases 
without JAK2 mutation. The frequency of diagnosis among 
the groups was found to be significantly different (p= 0.001, 
table 1).  
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Table 1. Relationship between the presence of JAK-2 mutation and variable of cases with thrombocytosis 
 
 JAK2  (+) 
n: 58 
JAK 2 (-) 
n:78 
P-value 
Age (Mean±SD) years  60.7±15.9 53.7±14.2 0.004 
Gender 
Male n (%) 
Female n (%) 
 
24 (41.4) 
34 (58.6) 
 
41 (52.6) 
37 (47.4) 
 
0.197 
platelet count (x 10
9 
/ L) 952±147 792.025±235 0.765 
Vertical spleen length (Mean±SD) 130.9±20.6 139.8±22.0 0.004 
Biopsy 
Performed  
Non-performed 
 
58 (54.8) 
0 90.0) 
 
48(45.2) 
30 (100) 
<0.001 
Definite diagnosis 
Essential thrombocytosis 
Inflammatory 
Iron deficiency anemia 
Myeloproliferative neoplasms (MPN) 
Splenectomy 
Primary myelofibrosis 
Policytemia vera 
Chronic myeloid leukemia 
Malignancy 
Myelodysplastic syndrome (MDS) 
MDS + MPN 
Autoimmune diseases 
 
33 (56.9) 
0 (0.0) 
0 (0.0) 
3 (5.2) 
0 (0.0) 
5 (8.6) 
16 (27.6) 
0 (0.0) 
0 (0.0) 
0 (0.0) 
1 (1.7) 
0 (0.0) 
 
26 (33.3) 
18 (23.1) 
8 (10.3) 
6 (7.7) 
5 (6.4) 
4 (5.1) 
3 (3.8) 
3 (3.8) 
2 (2.6) 
1 (1.3) 
1 (1.3) 
1 (1.3) 
 
 
<0.001 
 
Discussion 
Primary thrombocytosis and ET are more frequent in 
women and older ages. Clinically frequent thrombotic 
attacks, basal hemorrhage, splenomegaly, megakaryocytic 
hyperplasia in the bone marrow can be observed in ET (8).
 
Our findings suggest that patients with thrombocytosis in 
older age should be investigated in terms of primary 
thrombocytosis, as reactive thrombocytosis is less common 
in those ages. On the other side, the causes of reactive 
thrombocytosis, such as iron deficiency anemia and 
autoimmune diseases, are more common in the middle-aged 
women and also JAK2 mutation is negative. In recent years, 
JAK2 mutation has been a major criterion for CMDs and 
facilitated the differential diagnosis. The JAK2 mutation 
frequency was reported to be below 1% in the normal 
population, whereas it was 62.2% in CMD cases; 97.6% in 
PV cases; 54.5% in ET cases and 53.44% in PMF cases (9, 
10). ET, of which its annual incidence is 1-2 in 100.000 and 
was observed more commonly in the 60s, had the highest  
 
 
frequency of JAK2 positivity in our study. Approximately 
50% of ET patients were reported to have JAK2 mutation, 
greater blood cell counts and more complications than cases 
with JAK2 negative (11).  
JAK2 mutation was reported to be positive in 73% of PV 
patients, in 61% of ET cases, and in 55% of PMF cases in 
that study. The frequencies of JAK2-V617F mutation were 
reported to be 80% in the PV cases and 42 % in the ET cases 
in a study from Turkey. Leukocyte counts, hemoglobin 
values and the presence of splenomegaly were significantly 
different in patients with JAK2 mutation (12). In a study 
including 140 cases with CMDs, the rates of JAK2 mutation 
were found to be 82% (23.28) in PV cases, 53.1% (17.32) in 
ET patients, 40% (4.10) in PMF cases, and 60% (6.10) in 
other indistinguishable CMDs cases, respectively (7). In 
another study conducted in the 108 cases with CMDs cases 
in Taiwan by Liu et al, JAK2 mutation was found to be 
positive in 85% (28.33) PV cases, 59% of patients (29.49) in 
 Caspian J Intern Med 2018; 9(2): 189-193  
192                                                                                 Yokus O, et al. 
ET patients, 33% (2.6) in PMF cases, (0.11) in MDS 
patients, and (0.10) in the other cases with 10 different 
hematological diseases (13). In our study, the frequency of 
JAK2 mutation in the cases and mean age of the patients are 
lower than those in other studies. JAK2 mutation is more 
common in older adults and they have a higher risk of 
thrombosis (10). The mean of spleen vertical lengths was 
greater in cases with JAK2 mutation in our study, as JAK2 
mutation was reported to be more common in ET patients 
with organomegaly (13). The frequency of the JAK2 
mutation was reported to be insignificant between men and 
women with thrombocytosis in a study from Turkey (14).  It 
was reported that there is a relationship between the presence 
of JAK2 mutation and risk factors related to complications, 
such as advanced age at diagnosis, presence of the higher 
leukocyte count, itching, organomegaly, and larger spleen 
sizes (15, 16).   
This is more likely associated between the JAK2 
mutation and splenomegaly. However, there was not a 
relationship found between the presence of JAK2 mutation 
and splenomegaly in cases with BCR‑ABL negative CMDs 
in a study from Turkey (14).
 
Since cases with thrombocytosis 
were assessed only in terms of the frequency of JAK-2 
mutation in that study and the frequencies were found to be 
different from those in other studies that assessed the 
frequency of JAK-2 mutation in cases with 
BCR‑ABL‑negative CMDs (12, 17). The limitation of our 
study is that a limited number of cases with thrombocytosis 
were evaluated in terms of JAK2 mutation, retrospectively.  
There is a need to study greater number of cases from 
different hematology clinics to describe the exact frequency 
of JAK2 in cases with primary thrombocytosis from Turkey. 
However, our findings were different from other studies 
conducted in Turkey. It is obvious that the frequency of 
JAK2 mutation and other risk factors related to 
complications may vary by country and study population. 
The prospective and big populations include studies  needed 
to be defined appropriately. 
JAK2 mutation analysis and bone marrow biopsy are two 
main procedures to diagnose primary thrombocytosis in 
adults with persistent thrombocytosis after excluding the 
causes of secondary thrombocytosis. Myeloproliferative 
neoplasms and essential thrombocytosis are the common 
causes of primary thrombocytosis in adults with persistent 
thrombocytosis, as myelodysplastic syndrome rarely causes 
primary thrombocytosis. The ratios of primary and 
secondary ET cases in the etiology of thrombocytosis vary 
by age and hematology clinic where the study is conducted. 
JAK2 mutation analysis and then a bone marrow biopsy 
might be a reasonable way to confirm the definite diagnosis 
after assessment of the characteristics of patients with 
thrombocytosis and causes of reactive thrombocytosis.  
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